1,160
Views
13
CrossRef citations to date
0
Altmetric
Short Communication

Cancer stem cells CD133 inhibition and cytotoxicity of certain 3-phenylthiazolo[3,2-a]benzimidazoles: design, direct synthesis, crystal study and in vitro biological evaluation

, , , , , , , & show all
Pages 986-991 | Received 25 May 2017, Accepted 21 Jun 2017, Published online: 20 Jul 2017

Figures & data

Figure 1. Judicious design of target 3-phenylthiazolo[3,2-a]benzimidazoles (Series 2) based on cyclisation of disclosed compounds 2-((benimidazol-2-yl)thio)-1-arylethan-1-ones (Series 1).

Figure 1. Judicious design of target 3-phenylthiazolo[3,2-a]benzimidazoles (Series 2) based on cyclisation of disclosed compounds 2-((benimidazol-2-yl)thio)-1-arylethan-1-ones (Series 1).

Scheme 1. Synthesis of target 3-phenylthiazolo[3,2-a]benzimidazoles 4a–d.

Scheme 1. Synthesis of target 3-phenylthiazolo[3,2-a]benzimidazoles 4a–d.

Figure 2. An ORTEP diagram of final X-ray structure of compound 4d.

Figure 2. An ORTEP diagram of final X-ray structure of compound 4d.

Table 1. Crystallographic data and refinements for compound 4d.

Table 2. Hydrogen-bond geometry (Å, °) of 4d.

Table 3. In vitro anti-proliferative activity of compounds 4a–d against colon HT-29 and breast MDA-MB-468 cancer cell lines.

Table 4. Inhibition (%) of cell surface expression of CD133 on HT-29 cancer cells at 10 μM.

Supplemental material

IENZ_1347166_Supplementary_Material.pdf

Download PDF (566.7 KB)